secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2026-06-24T10:32:11+00:00
Accession:  0001672688-26-000118
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci reports positive interim Phase 1 data for ABS-201; half-life ≥65 days supports dosing 2-3 times/6 months
--------------------------------------------------------------------------------

- No serious adverse events; TEAEs were mild except one moderate headache deemed unrelated to treatment.
- Estimated half-life of at least 65 days across all four SAD cohorts (150–1800 mg IV).
- MAD portion in androgenetic alopecia participants initiated; interim PoC data expected H2 2026.
- Phase 2 trial for endometriosis planned later this year.
- 32 healthy volunteers enrolled in four SAD cohorts; data cutoff June 8, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/0001672688-26-000118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/absc-20260624.htm
  HTML page:      https://secwatch.observer/filing/0001672688-26-000118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer